Photo: poba/Getty Images
Cleveland Clinic is collaborating with Dyania Health, an AI-enabled healthcare data company, to integrate Dyania's Synapsis AI platform across Cleveland Clinic's clinical research enterprise.
Synapsis AI utilizes medically trained LLMs to gather and interpret data, including clinical notes, medical records, imaging and pathology, and combine it with other information, such as organ function or age, to draw precise medical conclusions.
The announcement comes in the wake of successful pilot programs in cardiology and oncology, as well as an effort where the teams jointly validated the technology's efficacy in neurology during a testing period.
The two companies aim to accelerate clinical trial recruitment by leveraging the LLMs to expedite and scale patient identification for research studies.
Additionally, by utilizing AI to automate chart review and identify eligible participants, the two organizations aim to address clinical trial enrollment bottlenecks and expand patient access to therapies.
In the pilot program, a Cleveland Clinic research team evaluated Synapsis AI next to two experienced research nurses for a melanoma trial.
Overall, the technology recognized an appropriate trial patient in 2.5 minutes with a 96% accuracy rate compared to 95% accuracy in 427 minutes by a melanoma-specialized nurse and 88% accuracy in 540 minutes by an oncology research nurse.
Likewise, in collaboration with the Heart, Vascular and Thoracic Institute, the platform was utilized to screen patients for the DepleTTR-CM trial, a Phase 3 study in transthyretin amyloid cardiomyopathy, a rare, progressive and potentially fatal disease of the heart muscle.
"Through our collaboration with Dyania Health, we are leveraging their AI platform to accelerate clinical trials and create a research infrastructure that benefits both investigators and patients," Dr. Lara Jehi, Cleveland Clinic chief research information officer, told MobiHealthNews.
"The technology’s ability to rapidly analyze complex medical data and identify potential patients for studies complements the expertise of healthcare professionals. Additionally, its success across multiple specialties and potential to improve access to care for underrepresented populations further underscore its value.”
Dyania Health founder and CEO Eirini Schlosser noted that the company's work is about unlocking possibilities that have been hidden in unstructured medical data for too long.
"By scaling Synapsis AI across Cleveland Clinic, we are transforming clinical research into something more proactive and inclusive, where eligible patients are surfaced in real time, investigators have greater confidence in their cohorts, and discoveries move from concept to care faster," Schlosser told MobiHealthNews.
THE LARGER TREND
Earlier this month, Cleveland Clinic-led research revealed that a bundled system of technology-driven interventions, utilizing AI to deliver personalized health insights and lifestyle recommendations, could improve glycemic control in adults with type 2 diabetes.
Results of the study published in the New England Journal of Medicine Catalyst showed that 71% of study participants using the bundled intervention system met the primary endpoint of achieving an A1C of 6.5% with less medications.
In 2024, a survey by the Cleveland Clinic and Amwell concluded that despite the growing demand for virtual healthcare solutions, patients still harbor concerns about the use of AI in medical diagnosis.
The survey found the availability of virtual second opinion (VSO) services made it far more likely for respondents to follow through with seeking a second opinion, with 89% noting they would be very or somewhat interested in obtaining a VSO if faced with a significant medical decision.
That same year, Dyania Health closed a $10 million Series A funding round led by HealthX, TechSquare and Cleveland Clinic Ventures, with participation from existing investors.
The company used the funds to further develop its Synapsis AI platform.
